ARCH Venture Partners

ARCH Venture Partners is a Chicago-based venture capital firm founded in 1986 that focuses on seed and early-stage investments in life sciences, biotechnology, physical sciences, and information technology. The firm is known for co-founding companies directly alongside leading scientists, entrepreneurs, and researchers from academic institutions, corporate research groups, and national laboratories. ARCH backs companies from the earliest concept stage, with investment sizes ranging from as little as $50K to hundreds of millions per company. Its most recent vehicle, ARCH Venture Fund XIII, closed in September 2024 at more than $3 billion — the firm's largest fund to date — and targets early-stage biotech companies with a growing emphasis on AI and data-driven biology. Notable portfolio companies include Illumina, Alnylam Pharmaceuticals, Juno Therapeutics, Beam Therapeutics, Grail, and Xaira Therapeutics. The firm maintains offices in Chicago, IL and Seattle, WA.